Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2025-04-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2024年年度报告
Regulatory Filings
2025-04-21 Chinese
北京双鹭药业股份有限公司2024年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the 2024 profit distribution plan. It details the proposed cash dividend per share, total dividend amount, and the rationale behind the distribution plan. It includes audited profit figures and references to board and supervisory meetings approving the plan. The document is relatively short (2095 characters) and focuses on the dividend distribution proposal rather than the full financial report or detailed earnings data. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related details for shareholders.
2025-04-21 Chinese
北京双鹭药业股份有限公司2024年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2024 年度财务决算报告' which translates to '2024 Annual Financial Settlement Report'. It contains detailed financial data including total assets, liabilities, net assets, revenue, profit, cash flow, and comparative figures for 2023 and 2024. The presence of comprehensive financial statements and analysis for the full fiscal year indicates this is a full annual financial report. The document length is 1716 characters, which is relatively short but contains substantive financial data, not just an announcement or summary. Therefore, it is classified as an Annual Report (10-K equivalent). FY 2024
2025-04-21 Chinese
北京双鹭药业股份有限公司拟续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (auditor) for the upcoming fiscal year 2025. It details the auditor's qualifications, independence, audit fees, and the approval process by the board and audit committee. It does not contain any actual financial statements or audit reports, but rather is a formal notice about the auditor appointment to be approved at the next shareholders' meeting. The document length is 3018 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement about auditor appointment rather than the audit report itself or an annual report.
2025-04-21 Chinese
第九届董事会独立董事专门会议第四次会议审核意见
Board/Management Information Classification · 95% confidence The document is a detailed report of a meeting of the independent directors of the company's board, reviewing and approving various company matters such as the 2024 profit distribution plan, internal control self-evaluation report, use of funds for short-term risk investment, external guarantees, and related party transactions. It includes voting results and independent opinions on these matters. The content focuses on board/management oversight and governance-related approvals rather than financial results or earnings. It is not an announcement of a report publication but a substantive meeting report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2025-04-21 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the 2024 fiscal year, including the 2024 Annual Report, Annual Supervisory Board Work Report, 2024 Financial Final Accounts Report, 2024 Profit Distribution Plan, Internal Control Self-Evaluation Report, and the appointment of the audit firm for 2025. It also includes approval of the 2025 Q1 report and other operational matters. The document is a formal announcement of the Supervisory Board's meeting decisions and approvals, not the reports themselves. The document length is 3393 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of meeting resolutions and approvals, not the full annual report or financial statements themselves.
2025-04-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.